In recent years, a number of genetic alterations in driver genes have been detected in refractory advanced luminal breast cancer (LBC), such as actionable mutations in PIK3CA, provoking the rapid development of targeted therapies in the clinic, including PI3K inhibitors.4, 5. This evidence concerns the gene PIK3CA and CDH1-related diffuse gastric and lobular breast cancer syndrome.